2025-10-24 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals (RXRX), incorporating the provided data.

## RXRX Stock Analysis

**Company Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **RXRX Cumulative Return:** -2.46%
*   **VOO Cumulative Return:** 41.08%
*   **Cumulative Return Difference:** -43.54%

**Analysis:** RXRX has significantly underperformed the S&P 500 over the period covered by the cumulative return data.

*   **Disparity Range:** Max: 84.1, Min: -64.3, Current: -45.5, Relative Disparity: 12.7

**Analysis:** The relative disparity of 12.7 suggests that RXRX's current underperformance is closer to its historical worst relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
| ---------- | ------ | ----- | ------ | ---- | ------ |
| 2021-2023  | 22.0% | 81.0% | 26.0% | -0.2 | 4.0    |
| 2022-2024  | 11.0% | 81.0% | -10.0% | 0.1  | 2.8    |
| 2023-2025  | 40.0% | 80.0% | -24.0% | 0.1  | 2.5    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows volatile performance across the different periods.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, indicating substantial risk.
*   **Alpha:** The alpha values are inconsistent. Negative alpha indicates underperformance relative to the market benchmark, considering risk.
*   **Beta:** The beta values are relatively low.

### 2. Recent Stock Price Fluctuations

*   **Current Price:** 6.11
*   **Last Market Data:** Price: 5.73, Previous Close: 5.75, Change: -0.35
*   **5-Day Moving Average:** 6.36
*   **20-Day Moving Average:** 5.54
*   **60-Day Moving Average:** 5.25

**Analysis:**

*   The current price (6.11) is above the 20-day and 60-day moving averages, suggesting a short-term upward trend.  However, it is below the 5-day moving average, indicating potential near-term pullback.
*   The last market data shows a slight price decrease, indicating a potential recent downward pressure.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 58.13
*   **PPO:** 1.44
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (195 shares - Very Safe - MRI:0.90) Monthly invest 1.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Recent (20-day) Relative Disparity Change:** 3.6 (+) - Short-term increase
*   **Expected Return:** -30.0% (Long-term underperformance vs. S&P 500)

**Analysis:**

*   The MRI of 0.9 suggests a generally favorable market environment for investment.
*   The RSI of 58.13 is neutral, indicating neither overbought nor oversold conditions.
*   The PPO of 1.44 indicates that the short-term moving average is above the long-term moving average, suggesting a potential upward trend.
*   The Hybrid Signal recommends a full allocation to RXRX, but this should be viewed cautiously given the other data points.
*   The recent increase in relative disparity suggests that RXRX is starting to close the gap with the S&P 500, but the expected return is still significantly negative.

### 4. Recent News & Significant Events

*   **[2025-10-22]** Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know (Zacks)
*   **[2025-10-22]** Jim Cramer on Recursion Pharmaceuticals: “Now, It’s a Meme Stock” (Insider Monkey)
*   **[2025-10-21]** Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings (Insider Monkey)
*   **[2025-10-21]** Up 25% in 1 Month, Is This Stock a Buy? (Motley Fool)
*   **[2025-10-20]** Is Recursion Pharmaceuticals Set for Further Gains After Recent 36% Share Price Surge? (Simply Wall St.)
*   **[2025-10-20]** Recursion Pharmaceuticals (RXRX) Is Up 6.0% After New AI Partnerships and Exscientia Acquisition Has the Bull Case Changed? (Simply Wall St.)

**Analysis:**

*   Recent news is mixed. While some articles highlight recent surges and potential for gains, others mention underperformance and a "meme stock" characterization.  The AI partnerships and Exscientia acquisition seem to be driving positive sentiment.

### 4-2. Analyst Opinions

*   **Consensus:** Hold
*   **Mean:** 2.62 (~Hold)
*   **Opinions:** 6
*   **Target Price:** Avg: 6.47 / High: 10.00 / Low: 3.00

**Analysis:**

*   The analyst consensus is "Hold" with a mean rating suggesting a neutral stance.
*   The average target price is slightly above the current price, suggesting modest upside potential. The wide range between the high and low target prices indicates significant uncertainty.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출      |
| ---------- | ----- | --------- |
| 2025-08-05 | -0.41 | 0.02 B$  |
| 2025-05-05 | -0.5  | 0.01 B$  |
| 2024-11-06 | -0.34 | 0.03 B$  |
| 2024-08-08 | -0.4  | 0.01 B$  |
| 2025-08-05 | -0.4  | 0.01 B$  |

**Analysis:**

*   The company is consistently unprofitable, with negative EPS across all reported quarters.
*   Revenue is relatively low and fluctuates.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
| ---------- | -------- | ------------- |
| 2025-06-30 | $0.02B  | -5.54%        |
| 2025-03-31 | $0.01B  | -47.31%       |
| 2024-12-31 | $0.00B  | -183.62%      |
| 2024-09-30 | $0.03B  | 53.69%        |
| 2024-06-30 | $0.01B  | 36.14%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE       |
| ---------- | -------- | --------- |
| 2025-06-30 | $0.92B  | -18.70%   |
| 2025-03-31 | $0.93B  | -21.68%   |
| 2024-12-31 | $1.03B  | -17.29%   |
| 2024-09-30 | $0.52B  | -18.27%   |
| 2024-06-30 | $0.58B  | -16.69%   |

**Analysis:**

*   Revenue is inconsistent, and profit margins are generally negative, highlighting profitability challenges.  The quarters with positive profit margins (2024-09-30, 2024-06-30) are exceptions.
*   Equity is relatively high, but ROE (Return on Equity) is consistently negative, indicating the company is not generating profits from its equity.

### 7. Summary and Conclusion

RXRX presents a mixed picture.  While the Market Risk Indicator is positive and there has been some recent price momentum, significant concerns remain:

*   **Underperformance:** RXRX has significantly underperformed the S&P 500.
*   **Profitability:** The company is currently unprofitable, with negative EPS, inconsistent revenue, and negative ROE.
*   **Risk:** High Maximum Drawdown indicates significant risk.
*   **Analyst Sentiment:** Analysts are neutral on the stock.

**Overall:** RXRX is a high-risk, high-reward investment. The company's AI-driven approach to drug discovery holds promise, but its financial performance needs to improve significantly. The "meme stock" label is a red flag.  The recommendation is to be very cautious and conduct thorough due diligence before investing. It may be worthwhile to monitor their progress.

